“Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets”: Reply

ISTH Academy, Faculty / Presenters, 404871

OC 54.2 Comparison of Direct Oral Anticoagulants versus Low Molecular Weight Heparin in Primary and Metastatic Brain Cancers: A Meta-Analysis and Systematic Review

ISTH Academy, Faculty / Presenters, 406407

OC 54.5 Association of Inferior Vena Cava Filter (IVCF) use and 30-Day Mortality and 180-Day Intracranial Hemorrhage Among Patients with Brain Metastasis and Venous Thromboembolism: An Updated Analysis

ISTH Academy, Faculty / Presenters, 406408

OC 64.4 Prediction of on Treatment Recurrent Venous Thromboembolism in Patients with Cancer: An Individual Patient Data Meta-Analysis of Randomized Controlled Trials

ISTH Academy, Faculty / Presenters, 406409

OC 64.5 Risk of On-Treatment Recurrent Venous Thromboembolism in Patients with Active vs Cured Cancer Patients: A Post-Hoc Analysis of Hokusai VTE Cancer

ISTH Academy, Faculty / Presenters, 406410

OC 71.2 Discharging Cancer Patients with Acute Pulmonary Embolism from the Emergency Department: A Multicenter Cohort Study

ISTH Academy, Faculty / Presenters, 406411

OC 46.4 Association of Growth Differentiation Factor-15 (GDF-15) with Thromboembolism and Mortality in Patients with Cancer: Findings from the Vienna Cats Study

ISTH Academy, Faculty / Presenters, 406412

OC 46.5 Tissue Factor Pathway Inhibitor is Associated with Risk of Venous Thromboembolism and All-Cause Mortality in Patients with Cancer

ISTH Academy, Faculty / Presenters, 406413

OC 71.1 Natural Language Processing for the Detection of Cancer-Associated Venous Thromboembolism

ISTH Academy, Faculty / Presenters, 406414

OC 71.3 The Prevalence of Relevant Drug-Drug Interactions and Associated Clinical Outcomes in Patients with Cancer-Associated Thrombosis on Concurrent Anticoagulation and Anticancer Therapies

ISTH Academy, Faculty / Presenters, 406415

OC 46.2 Plasma Protein Signature by Targeted Mass Spectrometry Allows Prediction of Venous Thromboembolism in Colorectal Cancer Patients with 90% Sensitivity

ISTH Academy, Faculty / Presenters, 406416

OC 64.2 Trends in Clinical Characteristics, Treatment and 30-Day Outcomes in Cancer Patients with Venous Thromboembolism from 2001 to 2020

ISTH Academy, Faculty / Presenters, 406417

OC 71.4 Management Patterns of Antithrombotics and Outcomes in Patients with Hematological Malignancy and Thrombocytopenia: A Prospective Registry (Matter Study)

ISTH Academy, Faculty / Presenters, 406418

OC 46.3 JAK2V617F-Positive Myeloproliferative Neoplasms are Associated with Impaired Fibrinolysis Both in Mice and Humans

ISTH Academy, Faculty / Presenters, 406419

OC 36.3 Epidemiologic Risk Predictors of Venous Thromboembolism (VTE) Among Cancer Patients Treated at U.S. Veterans Affairs (VA) Healthcare System

ISTH Academy, Faculty / Presenters, 406421

OC 36.1 External Validation of Novel Electronic Health Record (EHR) Risk Model for Cancer Associated Thrombosis in a Comprehensive Cancer Center

ISTH Academy, Faculty / Presenters, 406422

OC 17.1 The Association between Venous Thrombosis-Associated Genetic Variants and Coagulation Factor Levels and Thrombin Generation Potential

ISTH Academy, Faculty / Presenters, 406423

OC 17.5 Genetic Association of the 4q34.1 Locus with Residual Vascular Obstruction in Patients with Pulmonary Embolism

ISTH Academy, Faculty / Presenters, 406424

OC 09.4 C1-Inhibitor Levels and Venous Thromboembolism: Results from a Mendelian Randomization Study

ISTH Academy, Faculty / Presenters, 406425

OC 09.5 Identification and Validation of Novel Stabilin-2 Plasma Ligands

ISTH Academy, Faculty / Presenters, 406426

OC 17.4 Determining the Risk of Thrombosis in Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A Mutation using Population-Scale Genomics

ISTH Academy, Faculty / Presenters, 406427

OC 17.2 New Insights on the Genetics of Venous Thromboembolism Recurrence from a GWAS Analysis of 6,504 Patients Including 1,797 Recurrent Events

ISTH Academy, Faculty / Presenters, 406428

OC 34.1 Chronic Thromboinflammation Results in Cardiac Dysfunction in an Experimental Mouse Model of Deep Vein Thrombosis in a PAD4-Dependent Manner

ISTH Academy, Faculty / Presenters, 406429

OC 34.5 Very Long-Term Risk of Post-Thrombotic Syndrome after Deep Vein Thrombosis: The OPTIMEV Study

ISTH Academy, Faculty / Presenters, 406430

OC 34.3 Walking Capacity in Patients with Acute Deep Vein Thrombosis is Associated with the Location of Thrombosis and is Reduced in Patients with a History of Previous Deep Vein Thrombosis

ISTH Academy, Faculty / Presenters, 406431

OC 34.4 Post Thrombotic Syndrome in Idiopathic Upper Extremity Deep Vein Thrombosis

ISTH Academy, Faculty / Presenters, 406432

OC 01.4 Prevalence of Chronic Thromboembolic Pulmonary Hypertension and Evaluation of Thrombus Resolution in COVID-19-Associated Pulmonary Embolism Survivors

ISTH Academy, Faculty / Presenters, 406433

OC 34.2 Chronic Inflammatory Diseases Increase the Risk of Post-Thrombotic Syndrome: a Prospective Cohort Study

ISTH Academy, Faculty / Presenters, 406434

OC 09.2 Biomechanics, Energetics, and Structural Basis of Rupture of Fibrin Networks with Varying Density

ISTH Academy, Faculty / Presenters, 406435

OC 17.3 Prothrombotic Polymorphisms FV Leiden and Prothrombin G20210A in 699 Unrelated Patients with Congenital Antithrombin Deficiency: More than a Prognostic Value

ISTH Academy, Faculty / Presenters, 406436

OC 01.1 Discordance between Computed Tomography Pulmonary Angiography (CTPA) and Transthoracic Echocardiography (TTE) in Identification of Right Ventricular Strain in Patients with Acute Pulmonary Embolism

ISTH Academy, Faculty / Presenters, 406437

OC 72.5 Prediction of Venous Thromboembolism in Diverse Ancestry Populations Using Machine Learning and Electronic Health Records

ISTH Academy, Faculty / Presenters, 406438

OC 11.2 Pulmonary Embolism Diagnostic Strategies in Patients with COPD Exacerbation: Post-Hoc Analysis of the Pep Trial

ISTH Academy, Faculty / Presenters, 406439

OC 11.1 Development and Validation of a Clinical Prediction Model for the Diagnostic Management of Acute Pulmonary Embolism: An Individual Participant Data Meta-Analysis

ISTH Academy, Faculty / Presenters, 406440

OC 11.5 Diagnostic Strategies in Patients on Anticoagulation Presenting with a Suspicion of Recurrent Venous Thromboembolism

ISTH Academy, Faculty / Presenters, 406441

OC 11.3 Association between Body Mass Index and Pulmonary Embolism and Performance of the Age-Adjusted D-dimer Strategy in Obese Patients with Suspected Pulmonary Embolism: A Prospective Management Study

ISTH Academy, Faculty / Presenters, 406442

OC 11.4 Diagnosis of Deep Vein Thrombosis Using a D-Dimer Threshold Adjusted to Clinical Probability: Supportive Real-World Evidence for a Change in Clinical Practice

ISTH Academy, Faculty / Presenters, 406443

OC 40.3 High-Sensitivity Versus Conventional Troponin Cutoffs for Risk Stratification in Patients with Hemodynamically-Stable Acute Pulmonary Embolism

ISTH Academy, Faculty / Presenters, 406444

OC 63.4 Prevalence of Pulmonary Embolism in Patients with Chronic Obstructive Pulmonary Disease Exacerbation in North America – A Single Center Experience

ISTH Academy, Faculty / Presenters, 406445

OC 63.5 A Neural Network Approach to Predict Recurrent VTE Based on Coagulation Parameters

ISTH Academy, Faculty / Presenters, 406446

OC 72.2 Prevalence and Survival of Out-of-Hospital Cardiac Arrest Associated with Venous Thromboembolism – ASwedish Population-Based Cohort Study

ISTH Academy, Faculty / Presenters, 406447

OC 63.3 Combined Effect of High Factor VIII Levels and High Mean Platelet Volume on the Risk of Future Venous Thromboembolism

ISTH Academy, Faculty / Presenters, 406448

OC 21.1 Venous Thromboembolism and Vascular Access Thrombosis in Patients with End-Stage Kidney Disease on Hemodialysis: Prospective Results from the VIVALDI Study

ISTH Academy, Faculty / Presenters, 406449

OC 72.3 Risk of Pulmonary Embolism and Deep Vein Thrombosis Associated with Short-Term Air Pollution

ISTH Academy, Faculty / Presenters, 406450

OC 72.1 Knowledge of Venous Thromboembolism Among Nigeria Pregnant Women: A Preliminary Survey for the ‘Move for Flow’ Program

ISTH Academy, Faculty / Presenters, 406451

OC 63.2 Plasma Expression Levels of microRNA-145 are Associated with Risk of Future Venous Thromboembolism

ISTH Academy, Faculty / Presenters, 406452

OC 32.1 Risk Factors for Venous Thrombosis after Discharge from Medical Hospitalizations: The Medical Inpatient Thrombosis and Hemostasis (MITH) Study

ISTH Academy, Faculty / Presenters, 406453

OC 63.1 The Plasma Proteome and Risk of Venous Thromboembolism (VTE)

ISTH Academy, Faculty / Presenters, 406454

OC 72.4 Risk of Venous Thromboembolism (VTE) in First-Degree Relatives of Patients with VTE Compared with General Population VTE Risk

ISTH Academy, Faculty / Presenters, 406455

OC 40.1 Incidence of Bleeding and Recurrence in Isolated Distal Deep Vein Thrombosis. Findings from the TROLL Registry

ISTH Academy, Faculty / Presenters, 406456

OC 32.5 A New VTE Risk Score is Highly Effective to Prevent Maternal Death in Hospitalization during Pregnancy and in the Post-Partum: Results of a Prospective Trial

ISTH Academy, Faculty / Presenters, 406457

OC 36.5 Predictive Factors of Venous Thromboembolism Events in Multiple Myeloma: A French Cohort from 2012 to 2021

ISTH Academy, Faculty / Presenters, 406458

OC 32.3 Age, Race, D-Dimer, and Modified IMPROVE VTE Score did not Predict Effect of Thromboprophylaxis on Arterial Thromboembolism, Venous Thromboembolism, or Death after COVID-19 Hospitalization

ISTH Academy, Faculty / Presenters, 406459

OC 32.4 Predictors of Venous Thromboembolism Chemoprophylaxis in Hospitalized Medical Patients: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study

ISTH Academy, Faculty / Presenters, 406460

OC 09.3 Direct Oral Anticoagulants Improve Podocyte Health and Reverse Hypercoagulopathy in an Experimental Model of Glomerular Disease

ISTH Academy, Faculty / Presenters, 406461

OC 32.2 Risk of Venous Thromboembolism and Major Bleeding in Patients with Acute Medical Illness Receiving Thromboprophylaxis with Enoxaparin

ISTH Academy, Faculty / Presenters, 406462

OC 01.3 Systemic and Catheter-Directed Thrombolysis in High and Intermediate-High Risk Pulmonary Embolism: A Systematic Review with Meta-Analysis

ISTH Academy, Faculty / Presenters, 406463

OC 21.4 Patient-Relevant Bleeding Events Among Patients Taking Anticoagulant Medication

ISTH Academy, Faculty / Presenters, 406464

OC 21.5 Risk of Anticoagulant-Related Bleeding in Patients with Venous Thromboembolism. Results from a Large Non-Interventional Cohort

ISTH Academy, Faculty / Presenters, 406465

OC 40.2 Outcomes of Home Treatment of Acute Pulmonary Embolism in Clinically Relevant Patient Subgroups: A Systematic Review and Individual-Patient Data Meta-Analysis

ISTH Academy, Faculty / Presenters, 406466

OC 40.4 Effect of Previous INR Control on Subsequent DOAC Persistence and Adherence, in Patients Switched from VKA to DOAC

ISTH Academy, Faculty / Presenters, 406467

OC 40.5 Risk of All-Cause Mortality Following Anticoagulant Cessation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis

ISTH Academy, Faculty / Presenters, 406468

OC 01.2 Oxygen vs Ambient Air in Patients with Intermediate-Risk Acute Pulmonary Embolism: The Air Randomized Clinical Trial

ISTH Academy, Faculty / Presenters, 406469

OC 21.2 Safety of DOACs in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis

ISTH Academy, Faculty / Presenters, 406470

OC 71.5 Reasons for Anticoagulation Failure and Provider Management

ISTH Academy, Faculty / Presenters, 406471

OC 01.5 Anticoagulation Post-Pulmonary Endarterectomy: A Retrospective Cohort Study

ISTH Academy, Faculty / Presenters, 406472

OC 21.3 Association of Type of Oral Anticoagulation with Risk of Bleeding in 45,114 Patients with Venous Thromboembolism during Initial and Extended Treatment – A Nationwide Register Study

ISTH Academy, Faculty / Presenters, 406473

OC 35.3 Correlation between ETP-Based APC Resistance and the Relative Risk of Venous Thromboembolism in Women Using Combined Oral Contraceptives

ISTH Academy, Faculty / Presenters, 406474

OC 35.4 Longitudinal Profile of Estrogen-Related Thrombotic Biomarkers after Cessation of Combined Hormonal Contraceptives : The Prospective PILL-OFF Study

ISTH Academy, Faculty / Presenters, 406475

OC 35.1 Response of Thrombin Generation to Rivaroxaban in Twin-Families: Influence of Sex and Contraceptives

ISTH Academy, Faculty / Presenters, 406476

OC 25.5 Endothelial Damage and Complement Dysregulation in Fetuses from Mothers with Preeclampsia

ISTH Academy, Faculty / Presenters, 406477

OC 35.5 Epidemiology of Antithrombotic Therapy during Pregnancy in the Netherlands (2013–2019)

ISTH Academy, Faculty / Presenters, 406478

OC 02.5 Prospective Study on the Peripartal Loss of Coagulation Factors and Postpartum Hemorrhage in More than 1300 Parturient Women – the PPH-1300 Study

ISTH Academy, Faculty / Presenters, 406479

OC 25.4 Preventing Postpartum Venous Thromboembolism with Low-Molecular-Weight Heparin: A Feasibility Randomized Controlled Trial

ISTH Academy, Faculty / Presenters, 406480

OC 02.4 Women with Severe Postpartum Hemorrhage Have a Decreased Endogenous Thrombin Potential Before Delivery

ISTH Academy, Faculty / Presenters, 406481

OC 25.3 A Multicentre Cohort Study Evaluating Pregnancy Loss in Patients with Von Willebrand Disease and Unspecified Bleeding Disorders

ISTH Academy, Faculty / Presenters, 406482

OC 02.3 OC 02.3 Risk Factors for Severe Postpartum Hemorrhage after Assisted Reproductive Technology: Data from the French HEMOTHEPP Cohort Study

ISTH Academy, Faculty / Presenters, 406483

OC 35.2 The Role of Anti-Factor-Xa in the Dosing and Administration of Low Molecular Weight Heparins in Pregnancy: A Systematic Review and Meta-Analysis

ISTH Academy, Faculty / Presenters, 406484

OC 02.2 Pregnancy and Inherited Bleeding Disorders Study: Interim Safety Analysis after Revision of the Dutch Guideline

ISTH Academy, Faculty / Presenters, 406485

OC 25.2 Prevalence and Risk Factors for Thromboembolism in Women with Sickle Cell Disease during Pregnancy

ISTH Academy, Faculty / Presenters, 406486

OC 25.1 Platelet Derived Growth Factor-B is Increased during Intrauterine Growth Restriction Induced by Thromboxane A2

ISTH Academy, Faculty / Presenters, 406487

OC 02.1 Dose-Dependent Elimination of HPA-1a Platelets by Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

ISTH Academy, Faculty / Presenters, 406488

PB0004 A Case of Bivalirudin Associated Diffuse Alveolar Hemorrhage following Percutaneous Coronary Intervention

ISTH Academy, Faculty / Presenters, 406489

PB0005 The Interest of the Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in the Prediction of Thrombus in Myocardial Infarction

ISTH Academy, Faculty / Presenters, 406490

PB0002 Transient New-Onset Atrial Fibrillation is Associated with Poor Clinical Outcomes in Patients with Acute Myocardial Infarction

ISTH Academy, Faculty / Presenters, 406491

PB0003 Clinical Outcomes and Associated Factors in Patients who Underwent Successful Percutaneous Coronary Intervention: A 5-Year Multicenter Retrospective Study from a Developing Country

ISTH Academy, Faculty / Presenters, 406492

PB0001 Force Balance Ratio is a Robust Predictor of Arterial Thrombus Embolization

ISTH Academy, Faculty / Presenters, 406493

PB0008 Increased Levels of Plasma Cell-Free DNA are Associated with Symptomatology in Patients with Carotid Stenosis and are Independent of Plasma DNaseI Activity

ISTH Academy, Faculty / Presenters, 406494

PB0006 Investigation of the Antiplatelet, Antioxidant and Anti-Inflammatory Potency of Berries Extracts

ISTH Academy, Faculty / Presenters, 406495

PB0025 Collagen Remodeling, Inflammatory Biomarkers and Fatty Acid Regulation in Understanding the Molecular Pathogenesis of Atrial Fibrillation

ISTH Academy, Faculty / Presenters, 406496

PB0024 Left Atrial Appendage Closure (LAAC) as an Alternative to Oral Anticoagulation (OACs) in Patients with Atrial Fibrillation (AF): A Single Centre Experience

ISTH Academy, Faculty / Presenters, 406497

PB0022 Impact of COVID-19 on Thromboembolic Events and Mortality among Patients with Non-Valvular Atrial Fibrillation Receiving Oral Anticoagulants

ISTH Academy, Faculty / Presenters, 406498

PB0023 Oral Anticoagulants in Patients with Atrial Fibrillation and Comorbid Conditions

ISTH Academy, Faculty / Presenters, 406499

PB0019 Direct Oral Anticoagulants and Risk of Kidney Disease

ISTH Academy, Faculty / Presenters, 406500

PB0020 Anticoagulation Discharge Treatment Recommendations in Patients Admitted with a First-Time Diagnosis of Atrial Fibrillation

ISTH Academy, Faculty / Presenters, 406501

PB0021 Clinical Outcomes of Direct Oral Anticoagulants in Patients with Concomitant Use of Antiepileptic Drugs in the Real-World Registry MACACOD

ISTH Academy, Faculty / Presenters, 406502

PB0018 Direct Oral Anticoagulant Plasma Levels in Patients with Low Body Weight: A Retrospective Study

ISTH Academy, Faculty / Presenters, 406503

PB0016 Plasma Protein Carbonylation is Associated with Unfavorably Altered Fibrin Clot Properties in Patients with Atrial Fibrillation: A Novel Risk Factor of Ischemic Cerebrovascular Events

ISTH Academy, Faculty / Presenters, 406504

PB0015 Potential of Racial Bias in Atrial Fibrillation Patients that are Switched from Warfarin to a Direct Oral Anticoagulant

ISTH Academy, Faculty / Presenters, 406505

PB0014 Do Antiphospholipid Antibodies Inform the Choice of Anticoagulant Agents in Patients with Atrial Fibrillation?

ISTH Academy, Faculty / Presenters, 406506